Syntermed's NeuroQ™ 3.7 for SPECT Brain Imaging to Be Previewed at SNMMI

Share Article

In 2013 Syntermed, Inc. received 510K clearance from the Food and Drug Administration for NeuroQ™ 3.6, software used in nuclear medicine clinics for PET-FDG brain scans plus an additional clearance for the its amyloid brain uptake imaging application. As a work in progress, that 510K clearance extends to Syntermed’s newest nuclear medicine software, NeuroQ 3.7 for SPECT brain imaging quantification.

NeuroQ brain imaging software

Syntermed's NeuroQ 3.7 with amyloid uptake screenshot

NeuroQ is well established and being utilized in nuclear medicine labs worldwide for the quantitation of PET-FDG and recently Amyloid brain imaging studies, so adding SPECT was a logical next step. -- Michael Lee, Syntermed, Inc.

Past News Releases


Syntermed, Inc. will preview its newest brain imaging software for SPECT quantification, NeuroQ™ 3.7 (as a work in progress) at the Society of Nuclear Medicine and Molecular Imaging annual meeting June 7-10 in St. Louis, MO.

“NeuroQ is well established and being utilized in nuclear medicine labs worldwide for the quantitation of PET-FDG and recently Amyloid brain imaging studies, so adding SPECT was a logical next step. ” announced Michael Lee, CEO, Syntermed, Inc. “Radiologists and their departments will now have a single platform with NeuroQ 3.7 capable of supporting the most relevant functional imaging modalities for differential diagnosis of dementia.”

“Initial validation of NeuroQ 3.7 for SPECT analysis has demonstrated accurate results reducing the variability of the final results,” added Ken Van Train, President, Syntermed. “NeuroQ 3.7 will use the similar standardized region of interest (ROI) method to analyze the distribution for SPECT, plus the interface functions and reporting output shall be the same as with FDG and Amyloid, so the learning curve should be very quick.”

Within this area of imaging, NeuroQ software analyzes hard to detect differences within the brain study and automatically calculates the values within pre-defined regions of the brain to assist with the final interpretation of the images by the nuclear medicine specialist. NeuroQ also benefits the clinician and patient by being able to perform side-by-side comparable analysis from two studies of the same patient done at two points in time. “The differential diagnosis of dementia is complex and being able to quantify disease progression is very important to the clinicians using NeuroQ in their nuclear medicine labs,” adds Lee.

“Our belief is that in this era of personalized medicine, the physician and nuclear medicine lab technologists need access to tools that can enhance workflow and improve quantitative analysis of the final diagnostic interpretation,” says Lee. “For example, Syntermed’s NeuroQ amyloid brain uptake application is a niche application, not every lab performs these studies, but those that do should have the flexibility within their NeuroQ software to analyze the distribution of FDG and amyloid PET tracers in the brain and calculate the density of the beta-amyloid neuritic plaque with efficiency and a high degree of accuracy.”

In related news, Dan Silverman, MD, will be presenting the 2014 NeuroPET preceptor training course on June 7 and Syntermed is providing the educational grant for the SNMMI training course. Dr. Silverman will address Brain PET applications for many neurologic diseases and discuss quantification issues for Brain PET-FDG, SPECT brain imaging and amyloid update studies as it applies to patient management within the clinical practice.

About Syntermed, Inc.: An Atlanta-based imaging and infomatics software company supporting SPECT and PET imaging for heart and brain studies with quantification and decision support software. Signature products: Emory Toolbox, now in it's fourth generation, utilized by nuclear cardiology labs worldwide; SyncTool for advanced phase analysis imaging studies of left ventricle dyssynchrony; NeuroQ for PET-FDG brain imaging used in the differential diagnosis of dementia. Michael Lee, CEO, and Ken Van Train, President, both will be available at the SNMMI meeting, June 7-10, at the Syntermed booth to provide additional details about Syntermed's pipeline products and market expansion.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Roberts

Micheal Lee
Follow us on
Visit website